Olaratumab-induced Biomarker Modulation in Sarcomas-Response

Mol Cancer Ther. 2021 Oct;20(10):2094. doi: 10.1158/1535-7163.MCT-21-0497.

Authors

Javier Martín-Broto¹, Patrick M Peterson², Gerard J Oakley³, Matteo Ceccarelli⁴, Robin L Jones⁵

Affiliations

¹ Oncology Department Fundación Jiménez Díaz University Hospital Av. Reyes Catolicos 2, 28040 Madrid.
² Institute of Biomedicine of Seville, University of Seville, Spain.
³ Eli Lilly and Company, Indianapolis, Indiana, USA.
⁴ Eli Lilly and Company, Sesto Fiorentino, Florence, Italy.
⁵ Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, United Kingdom. robin.jones4@nhs.net.

PMID: 34607902
DOI: 10.1158/1535-7163.MCT-21-0497

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal*
Biomarkers
Humans
Sarcoma*

Substances

Antibodies, Monoclonal
Biomarkers
olaratumab

Grants and funding

29363/CRUK_/Cancer Research UK/United Kingdom